Global Cardiac Troponin Market Size To Exceed USD 7.35 Billion By 2035 | CAGR Of 7.95%

Global Cardiac Troponin Market Size To Exceed USD 7.35 Billion By 2035

According to a research report published by Spherical Insights & Consulting, the Global Cardiac Troponin Market Size is Expected to Grow from USD 3.17 billion in 2024 to USD 7.35 billion by 2035, at a CAGR of 7.95% during the forecast period 2025-2035.

Browse key industry insights spread across 225 pages with 119 Market data tables and figures & charts from the report on the Global Cardiac Troponin Market Size, Share, and COVID-19 Impact Analysis, By Type (Troponin T and Troponin I), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Setting (Laboratory Testing and Point-Of-Care (POC) Testing), By End User (Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings & Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.  Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/cardiac-troponin-market

The cardiac troponin market refers to the industry encompassing the development, manufacturing, and distribution of tests and assays used for detecting and measuring cardiac troponin levels in the blood. Cardiac troponin (cTn) is a set of regulatory proteins unique to cardiac muscle, plays a crucial role in muscle contraction and relaxation. It serves as a specific biomarker for myocardial damage for the diagnosis of myocardial infarction (MI). Technological advancements, including the development of fully automated labs and product innovation, aid in propelling the market growth of cardiac troponin. Further, the integration of AI and machine learning into troponin testing for detecting the minuscule elevations in troponin levels during the early stages of a suspected heart attack is escalating the market growth opportunity. The growing prevalence of cardiovascular diseases is driving the demand for cardiac troponin for optimizing risk stratification in patients with chronic coronary artery disease. However, the lack of sensitivity of conventional assays for detecting the presence of small amounts of this protein is restraining the cardiac troponin market.

The troponin I segment accounted for the largest market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the cardiac troponin market is divided into troponin T and troponin I. Among these, the troponin I segment accounted for the largest market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Causes of raised troponin include myocardial infarction (MI), chronic kidney failure, heart failure, subarachnoid haemorrhage, and pulmonary embolus. Further, in veterinary medicine, ionotropic toxicity is found in cattle due to increased cTnI, which is responsible for MI. The growing advancement in troponin I diagnostic testing is propelling the market.

The laboratory testing segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the setting, the cardiac troponin market is divided into laboratory testing and point-of-care (POC) testing. Among these, the laboratory testing segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Estimating the amount of troponin in the blood helps in evaluating the extent of heart damage, which ultimately aids in diagnosing a heart attack. The detailed analysis provided by laboratory testing as compare to other tests, is driving the segmental market demand.

The acute coronary syndrome segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the indication, the cardiac troponin market is divided into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. Among these, the acute coronary syndrome segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The testing is essential for diagnostic workup and management of acute coronary syndromes (ACS) due to increased sensitivity to cardiac troponin levels. Furthermore, the increasing prevalence of acute coronary syndrome is driving market demand.

The hospitals & clinics segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the cardiac troponin market is divided into hospitals & clinics, diagnostic laboratories, and homecare settings & others. Among these, the hospitals & clinics segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The growing adoption of cardiac troponin tests by healthcare providers, as well as growing hospitalization rates, are driving the cardiac troponin market in the hospitals & clinics segment.

North America is expected to hold the majority share of the global cardiac troponin market during the forecast period.

North America is expected to hold the majority share of the global cardiac troponin market during the forecast period. The heightened demand for troponin testing among COVID-19 patients, significantly driving the market growth. The increasing prevalence of cardiovascular disease in the US, along with an increasing product approvals by the regulatory bodies, aids in propelling the cardiac troponin market.

Asia Pacific is anticipated to grow at the fastest pace in the global cardiac troponin market during the forecast period. An increasing awareness regarding cardiac disease management programs is contributing to promoting market growth. The concerns regarding the increasing number of deaths due to cardiovascular diseases in East Asian countries like Japan, China, and Taiwan are driving the market demand for cardiac troponin.

Europe is anticipated to hold a significant share of the cardiac troponin market during the predicted timeframe. The increasing funds from private and public organizations for conducting research and clinical trials in biomarker testing are driving the market. The presence of key market players, including F. Hoffmann-La Roche Ltd., Eurolyser Diagnostica GmbH, and others, is responsible for the cardiac troponin market.

Major vendors in the global cardiac troponin market are F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott, Siemens Healthineers AG, Eurolyser Diagnostica GmbH, QuidelOrtho (Quidel Corporation), PerkinElmer Inc., Beckman Coulter, Inc. (Danaher), RESPONSE BIOMEDICAL, LifeSign LLC, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In May 2023, Bio-Rad Laboratories launched Cardiac Advanced, a four-level multianalyte cardiac quality control for high-sensitivity troponin testing.

• In February 2023, Pathology Queensland (PQ) announced that it had installed its highly sensitive cardiac troponin (hs-cTnl) assay.
•  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the cardiac troponin market based on the below-mentioned segments:

Global Cardiac Troponin Market, By Type

• Troponin T
• Troponin I

Global Cardiac Troponin Market, By Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others

Global Cardiac Troponin Market, By Setting

• Laboratory Testing
• Point-Of-Care (POC) Testing

Global Cardiac Troponin Market, By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare Settings & Others

 Global Cardiac Troponin Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter